Immunogenicity Management Strategies for PEGylated Drug Delivery Systems
Abstract The clinical translation and long-term efficacy of PEGylation technology are increasingly jeopardized by its inherent immunogenicity, particularly the induction of anti-PEG antibodies (APAs) and the subsequent accelerated blood clearance (ABC) phenomenon. Furthermore, challenges such as frequent dosing regimen...